Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-07-04

AUTHORS

Christopher H. Chu, Charles Davis

ABSTRACT

A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2 months and then one 45-mg injection every 3 months for her psoriasis. After 10 months, she developed a round red rash on her skin diffusely on her body. She also complained of joint pain in her hands. Rheumatology became involved, and investigations revealed that her antinuclear antibody titer was negative, but her rheumatoid factor, erythrocyte sedimentation rate, and liver function enzymes were elevated. She was diagnosed with urticaria, and ustekinumab was discontinued. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab. Ustekinumab was subsequently discontinued, and the patient received a course of Harvoni® (Gilead Sciences, Inc., Forest City, California, United States) (ledispasvir/sofosbuvir) with clearance of the hepatitis C virus. The patient is currently receiving another biologic agent, ixekizumab, and reports no complaints, including that of urticaria. More... »

PAGES

9

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40800-017-0051-2

DOI

http://dx.doi.org/10.1007/s40800-017-0051-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090347139

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28677075


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC 29209 USA", 
          "id": "http://www.grid.ac/institutes/grid.254567.7", 
          "name": [
            "School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC 29209 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chu", 
        "givenName": "Christopher H.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dorn VA Medical Center, Columbia, SC USA", 
          "id": "http://www.grid.ac/institutes/grid.417149.e", 
          "name": [
            "School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC 29209 USA", 
            "Dorn VA Medical Center, Columbia, SC USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davis", 
        "givenName": "Charles", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-88-470-5313-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015915373", 
          "https://doi.org/10.1007/978-88-470-5313-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07-04", 
    "datePublishedReg": "2017-07-04", 
    "description": "A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2\u00a0months and then one 45-mg injection every 3\u00a0months for her psoriasis. After 10\u00a0months, she developed a round red rash on her skin diffusely on her body. She also complained of joint pain in her hands. Rheumatology became involved, and investigations revealed that her antinuclear antibody titer was negative, but her rheumatoid factor, erythrocyte sedimentation rate, and liver function enzymes were elevated. She was diagnosed with urticaria, and ustekinumab was discontinued. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab. Ustekinumab was subsequently discontinued, and the patient received a course of Harvoni\u00ae (Gilead Sciences, Inc., Forest City, California, United States) (ledispasvir/sofosbuvir) with clearance of the hepatitis C virus. The patient is currently receiving another biologic agent, ixekizumab, and reports no complaints, including that of urticaria.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40800-017-0051-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1052958", 
        "issn": [
          "2199-1162", 
          "2198-977X"
        ], 
        "name": "Drug Safety - Case Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "keywords": [
      "hepatitis C", 
      "plaque psoriasis", 
      "type 2 diabetes mellitus", 
      "antinuclear antibody titer", 
      "Naranjo assessment score", 
      "erythrocyte sedimentation rate", 
      "liver function enzymes", 
      "hepatitis C virus", 
      "ustekinumab injection", 
      "joint pain", 
      "positive patients", 
      "diabetes mellitus", 
      "biologic agents", 
      "antibody titers", 
      "rheumatoid factor", 
      "C virus", 
      "urticarial reaction", 
      "red rash", 
      "function enzymes", 
      "patients", 
      "white women", 
      "psoriasis", 
      "assessment scores", 
      "Ustekinumab", 
      "urticaria", 
      "months", 
      "probable relationship", 
      "sedimentation rate", 
      "treatment", 
      "injection", 
      "ixekizumab", 
      "mellitus", 
      "rash", 
      "pain", 
      "rheumatology", 
      "titers", 
      "complaints", 
      "Harvoni", 
      "clearance", 
      "women", 
      "skin", 
      "virus", 
      "scores", 
      "agents", 
      "course", 
      "factors", 
      "history", 
      "rate", 
      "enzyme", 
      "body", 
      "use", 
      "relationship", 
      "hand", 
      "investigation", 
      "reaction", 
      "round red rash", 
      "course of Harvoni"
    ], 
    "name": "Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient", 
    "pagination": "9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090347139"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40800-017-0051-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28677075"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40800-017-0051-2", 
      "https://app.dimensions.ai/details/publication/pub.1090347139"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_722.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40800-017-0051-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40800-017-0051-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40800-017-0051-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40800-017-0051-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40800-017-0051-2'


 

This table displays all metadata directly associated to this object as RDF triples.

132 TRIPLES      22 PREDICATES      84 URIs      75 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40800-017-0051-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nac308aad3ea2467689d67ea39b9695cb
4 schema:citation sg:pub.10.1007/978-88-470-5313-7
5 schema:datePublished 2017-07-04
6 schema:datePublishedReg 2017-07-04
7 schema:description A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2 months and then one 45-mg injection every 3 months for her psoriasis. After 10 months, she developed a round red rash on her skin diffusely on her body. She also complained of joint pain in her hands. Rheumatology became involved, and investigations revealed that her antinuclear antibody titer was negative, but her rheumatoid factor, erythrocyte sedimentation rate, and liver function enzymes were elevated. She was diagnosed with urticaria, and ustekinumab was discontinued. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab. Ustekinumab was subsequently discontinued, and the patient received a course of Harvoni<sup>®</sup> (Gilead Sciences, Inc., Forest City, California, United States) (ledispasvir/sofosbuvir) with clearance of the hepatitis C virus. The patient is currently receiving another biologic agent, ixekizumab, and reports no complaints, including that of urticaria.
8 schema:genre article
9 schema:inLanguage en
10 schema:isAccessibleForFree true
11 schema:isPartOf N9276aa6fa3f041428f8c7ae8a1856102
12 Nac4fbdd9b63647d9a50b238b5ce1226b
13 sg:journal.1052958
14 schema:keywords C virus
15 Harvoni
16 Naranjo assessment score
17 Ustekinumab
18 agents
19 antibody titers
20 antinuclear antibody titer
21 assessment scores
22 biologic agents
23 body
24 clearance
25 complaints
26 course
27 course of Harvoni
28 diabetes mellitus
29 enzyme
30 erythrocyte sedimentation rate
31 factors
32 function enzymes
33 hand
34 hepatitis C
35 hepatitis C virus
36 history
37 injection
38 investigation
39 ixekizumab
40 joint pain
41 liver function enzymes
42 mellitus
43 months
44 pain
45 patients
46 plaque psoriasis
47 positive patients
48 probable relationship
49 psoriasis
50 rash
51 rate
52 reaction
53 red rash
54 relationship
55 rheumatoid factor
56 rheumatology
57 round red rash
58 scores
59 sedimentation rate
60 skin
61 titers
62 treatment
63 type 2 diabetes mellitus
64 urticaria
65 urticarial reaction
66 use
67 ustekinumab injection
68 virus
69 white women
70 women
71 schema:name Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient
72 schema:pagination 9
73 schema:productId N23321f06557343bc99763cdc87f7583d
74 N41cfe7fd3d54436694744f890c83997f
75 N814bd687367a42b3a508b1f006ee20bf
76 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090347139
77 https://doi.org/10.1007/s40800-017-0051-2
78 schema:sdDatePublished 2021-12-01T19:39
79 schema:sdLicense https://scigraph.springernature.com/explorer/license/
80 schema:sdPublisher Nef62aac461bd4458b149aaef79176ff2
81 schema:url https://doi.org/10.1007/s40800-017-0051-2
82 sgo:license sg:explorer/license/
83 sgo:sdDataset articles
84 rdf:type schema:ScholarlyArticle
85 N17caa5e9dcb0486d971da451ba84f15e schema:affiliation grid-institutes:grid.254567.7
86 schema:familyName Chu
87 schema:givenName Christopher H.
88 rdf:type schema:Person
89 N23321f06557343bc99763cdc87f7583d schema:name pubmed_id
90 schema:value 28677075
91 rdf:type schema:PropertyValue
92 N2ead5925faf148eea588b85dc66cbc1b schema:affiliation grid-institutes:grid.417149.e
93 schema:familyName Davis
94 schema:givenName Charles
95 rdf:type schema:Person
96 N41cfe7fd3d54436694744f890c83997f schema:name doi
97 schema:value 10.1007/s40800-017-0051-2
98 rdf:type schema:PropertyValue
99 N58928a0ed6ce46ca9d815e59ac54cd94 rdf:first N2ead5925faf148eea588b85dc66cbc1b
100 rdf:rest rdf:nil
101 N814bd687367a42b3a508b1f006ee20bf schema:name dimensions_id
102 schema:value pub.1090347139
103 rdf:type schema:PropertyValue
104 N9276aa6fa3f041428f8c7ae8a1856102 schema:volumeNumber 4
105 rdf:type schema:PublicationVolume
106 Nac308aad3ea2467689d67ea39b9695cb rdf:first N17caa5e9dcb0486d971da451ba84f15e
107 rdf:rest N58928a0ed6ce46ca9d815e59ac54cd94
108 Nac4fbdd9b63647d9a50b238b5ce1226b schema:issueNumber 1
109 rdf:type schema:PublicationIssue
110 Nef62aac461bd4458b149aaef79176ff2 schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
113 schema:name Medical and Health Sciences
114 rdf:type schema:DefinedTerm
115 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
116 schema:name Clinical Sciences
117 rdf:type schema:DefinedTerm
118 sg:journal.1052958 schema:issn 2198-977X
119 2199-1162
120 schema:name Drug Safety - Case Reports
121 schema:publisher Springer Nature
122 rdf:type schema:Periodical
123 sg:pub.10.1007/978-88-470-5313-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015915373
124 https://doi.org/10.1007/978-88-470-5313-7
125 rdf:type schema:CreativeWork
126 grid-institutes:grid.254567.7 schema:alternateName School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC 29209 USA
127 schema:name School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC 29209 USA
128 rdf:type schema:Organization
129 grid-institutes:grid.417149.e schema:alternateName Dorn VA Medical Center, Columbia, SC USA
130 schema:name Dorn VA Medical Center, Columbia, SC USA
131 School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC 29209 USA
132 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...